Search Results - frank+bosmans

6 Results

Sort By:

Diagnostic and therapeutic target for primary dysautonomia

Value Proposition:· Diagnostic target for broad primary dysautonomia screening.· Broadly applicable therapeutic target for symptom relief in primary and secondary dysautonomia patients.Technology DescriptionResearchers at Johns Hopkins have identified a potential diagnostic and therapeutic target for patients with primary dysautonomia....

Published: 5/10/2024 | Inventor(s): Malcolm Brock, Frank Bosmans

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules

Rufinamide derivatives as novel drugs against epilepsy syndromes caused by aberrant sodium channel behavior

Unmet NeedLennox-Gastaut Syndrome (LGS) is rare and severe form of childhood-onset epilepsy associated with various types of seizures and cognitive dysfunction that persist into adulthood; yet, to date, LGS management is challenged by the lack of reliable diagnostic tests and potentially grave side-effects of available therapeutics. Rufinamide is a...

Published: 5/9/2024 | Inventor(s): Frank Bosmans, Dimpy Kalia

Keywords(s): Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Epilepsy, Genetic Disorders, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Epilepsy, Clinical and Disease Specializations > Rare Diseases

Snake Toxins and their Use as Pharmacological Modulators of GABAa Receptors

Ionotropic γ-aminobutyric acid type A (GABAA) receptors are found primarily in the central nervous system (CNS) where they mediate inhibitory post-synaptic transmission by increasing CI" conductance into the cell. However, GABAA receptor activation can be excitatory in neonatal neurons and dorsal root ganglia where intracellular CI" concentrations...

Published: 5/9/2024 | Inventor(s): Pierre Bougis, Frank Bosmans

Keywords(s): Biologics, CNS and Neurological Disorders, Disease Indication, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities

Novel Triazole Compounds to Treat Nav1.6-related Brain Disorders

Unmet NeedAbnormal behavior of sodium (Nav) channels is linked to a variety of epilepsy syndromes, movement disorders, and neuropathic pain. While researchers continue to elucidate the roles of different Nav channel isoforms within a variety of neurological disorders, current therapeutics influence numerous Nav channel isoforms, resulting in off-target...

Published: 5/9/2024 | Inventor(s): Frank Bosmans, Dimpy Kalia

Keywords(s): Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Epilepsy, Neuropathy, Non-novel, Novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Neuropathy, Clinical and Disease Specializations > Neurology > Epilepsy

Novel Triazole Compounds to Treat Brain Disorders

Published: 5/9/2024 | Inventor(s): Frank Bosmans, Jeet Kalia

Keywords(s): Antagonists/Inhibitors, Assay, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, Epilepsy, In Vitro Diagnostics, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Epilepsy, Technology Classifications > Research Tools > Assays

A Surface Plasmon Resonance Approach to Monitor Animal Toxin Interactions with Isolated Voltage-gated Sodium Channel Paddle Motifs and the Use Thereof

Animal toxins that inhibit voltage-gated sodium (Nav) channel fast inactivation can do so through an interaction with the S3b-S4 helix-turn-helix motif, or paddle motif, located in the domain IV voltage sensor. Here, we show that the domain IV paddle can be lifted out of the Nav channel and immobilized on sensor chips. Subsequent Surface Plasmon Resonance...

Published: 5/9/2024 | Inventor(s): Pierre Bougis, Marie-France Eauclaire, Frank Bosmans

Keywords(s): Discovery/Research Tools, In Vitro Research Tool, Target-based Screening Tool

Category(s): Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools, Technology Classifications > Diagnostics, Technology Classifications > Research Tools > Assays